2012Annual &SpecialM ti f Sh h ldMeetingofShareholders

May8,2013

1. OpeningoftheMeetingAgenda

2. ChairmanandSecretary3. Scrutineers4. NoticeofMeeting5. ReportoftheScrutineers6. MinutesofthelastMeeting7. ConsolidatedFinancialStatementsandAuditorsReport

R ifi i f h f h Di8. RatificationoftheactsoftheDirectors9. ElectionofDirectors10 Appointment of Auditors and Fixing of their Remuneration10. AppointmentofAuditorsandFixingoftheirRemuneration

11.Increaseofmaximumofcommonsharesreservedforissuanceundertheamendedandrestatedstockoptionplanp p

12. RenewaloftheamendedandrestatedProMetic loanagreement13. Varia 2

Corporate Presentationp

ForwardLookingStatement/Copyrightnotice/ Disclaimer/Disclaimer

ForwardLookingStatementThis presentation contains forwardlooking statements about ProMetics objectives, strategies and businessesthat involve risks and uncertainties. These statements are forwardlooking because they are based on ourcurrent expectations about the markets we operate in and on various estimates and assumptions. Actual eventsor results may differ materially from those anticipated in these forwardlooking statements if known or unknowni k ff t b i if ti t ti t t t b i t S h i k drisks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks andassumptions include, but are not limited to, ProMetics ability to develop, manufacture, and successfullycommercialize valueadded pharmaceutical products, the availability of funds and resources to pursue R&Dprojects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage ofbusiness opportunities in the pharmaceutical industry, uncertainties related to the regulatory process andgeneral changes in economic conditions. You will find a more detailed assessment of the risks that could causeactual events or results to materially differ from our current expectations in the Annual Information Form for theyear ended December 31, 2012, under the heading Risk Factors. As a result, we cannot guarantee that anyforwardlooking statement will materialize. We assume no obligation to update any forwardlooking statementeven if new information becomes available, as a result of future events or for any other reason, unless requiredby applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

Copyright noticeThe information contained in this presentation (including names, images, logos and descriptions portrayingProMetic's products and/or services) is the property of ProMetic Life Sciences Inc., of its divisions and / or of itssubsidiaries (ProMetic) and is protected by copyright, patent and trademark law and / or other intellectualproperty rights. Neither this presentation nor any part may be reproduced or transmitted in any form or by anyproperty rights. Neither this presentation nor any part may be reproduced or transmitted in any form or by anymeans, electronic or mechanical, including printing and photocopying, or by any information storage or retrievalsystem without prior permission in writing from ProMetic.

DisclaimerProMetic reserves the right to make improvements, corrections and/or changes to this presentation at any time.

4

ProMetic reserves the right to make improvements, corrections and/or changes to this presentation at any time.

ProMeticLifeSciencesInc.d i Introduction

2012FinancialResultsB i S t BusinessSegments: Smallmoleculetherapeutics

Protein Technologies:ProteinTechnologies: Bioseparation /filters

Plasmaderivedproteins

Q12013 2013Business:BaseCase

l k Outlook 2013Objectives

5

QuestionandAnswerPeriod

2012FinancialResults

The following information is derived from the auditedSourceofFinancialInformation

The following information is derived from the auditedconsolidated December 31, 2012 financial informationand on the statutory financial statements for 2011,and on the statutory financial statements for 2011,both of which were prepared in accordance withInternational Financial Reporting Standards (IFRS).

Further financial information, including the ProMetics, gAnnual Information Form, is available on SEDAR(www.sedar.com).

All tabulated sums are in CAD 000s except for pershare amounts or where indicated.

7

FinancialPerformancefor2012

Significantly improved financialperformance in 2012 with recordrevenues of $23.3 million exceedinganticipated base case of $21.0million.

P d t l f $11 6 illi Product sales of $11.6 million,Services revenues of $5.3 million andLicensing revenues totalling $6.4million.

Stronger total revenues and costgcontainment positively impactedEBITDA.

First EBITDA positive year in corporate$

8

history at $2.5 million.

ComparisonofKeyFinancials:P&LYearendedDecember31

2012CAD 000s

2011CAD 000sCAD000s CAD000s

Revenues 23,321 17,589

CostofGoods 5,326 1,854

Total Research & Development Costs 10 310 11 230TotalResearch&DevelopmentCosts 10,310 11,230

Administration&Marketing 5,966 5,789

FinanceCosts 1,483 1,363

NetLoss (424) (3,267)

NetLosspershare(basicanddiluted) (0.00) (0.01)

EBITDA* 2,498 (526)

*EBITDA is a nonGAAP measure, employed by the corporation to monitor its performance. Therefore it is unlikely to becomparable to similar measures presented by other companies. The corporation calculates its EBITDA by subtracting fromR it C t f G d S ld it R h d D l t E R h bl d N R h bl ll itRevenues, its Cost of Goods Sold, its Research and Development Expenses Rechargeable and NonRechargeable as well as itsAdministration and Marketing Expenses and excluding amortization of capital assets and licenses and patents.

9

ComparisonofKeyFinancials:B l Sh tBalanceSheet

YearendedDecember31

2012CAD000s

2011CAD000s

Cash 1,205 275

Accounts Receivable 4,750 1,438AccountsReceivable 4,750 1,438

ShareSubscriptionReceivable 9,822

BankandOtherLoans (1,636) (752)

Trade&OtherPayables (5,094) (7,091)

DeferredRevenues (2,355) (447)

LongtermDebtProvidedbyShareholders (4,017) (4,161)

AdvanceonRevenuesfromaSupplyAgreement (3,030) (3,063)

NetEquity(Deficiency) 5,819 (8,568)

BalanceSheetTotalAssets 22,991 8,692

10

BusinessSegment:SmallMolecule Therapeutics

USRDS2012AnnualDataReport

Medicare Population 2010 Medicare Costs 2010

12

RegulatoryStrategyKeyRegulatoryFilingMilestones&Timing:IVIGPBI4050 NewDatatobepresentedat

l fInternationalConferences

ERAEDTA(EuropeanRenalAssociation EuropeanDialysisandTransplantAssociation):Istanbul,1821May,2013.

W ld C f N h l H K 31 M 4 J 2013 WorldCongress ofNephrology:HongKong,31May 4June,2013.

Americanassociationforthestudyofliverdiseases:Washington15November , 2013November,2013

AmericanSocietyofNephrology:Atlanta,November11,2013

A i A i ti R i l C ti A h i N b 16 AmericanAssociationRespirology Convention:Anaheim,November162013

14

Value Probability

PhasesinDrugDevelopment&Relativevalue/ProbabilityofregulatoryApproval

100%$5000M

y

RegulatoryFiling

75%PhIII

50%

Ph Ib / II

$500MPh II

GLPTOXGMPAPI

fili

PhI

PhIb /II

+$250M

10%R&DDiscovery

PreclinicalProofofconcept

INDfilings

$50M$1.5M

2013

DevelopmentMilestoneTimelinesCTAHealthCanada

PreINDMeetingFDA/EMA/Health Canada

IND FDACTA

p

Tech transfer chemical synthesis

2013 2014Q1 Q2 Q3 Q4 Q1

CanadaHealthCanada

TechtransferchemicalsynthesisChemicalsynthesisscaleupGMPManufacturinginFDAplant

Pharmaco kineticsGLP T i l PGLPToxicologyProgramFinaldosageformulation

PhaseIHealthyl t

PhaseIb IIPatients

volunteers

BusinessSegment:gProtein Technologies

Bioseparation Enables the capture of multiple targeted proteins directly fromEnablesthecaptureofmultipletargetedproteinsdirectlyfrom

varioussourceproducts

Providesforahighlyefficientandcosteffectiveseparationprocessfromotherproteinsandimpuritiesdeliveringhighyieldsofpurifiedproduct

Results in significant reductions in clients cost of goods andResultsinsignificantreductionsinclient scostofgoodsandcostsassociatedtodrugpurification.

Protein PowerHouse

InitiationofacollaborativeagreementinJanuary2003tocodevelopanovelprocesstorecovertherapeutic proteins in a sequential manner from plasmatherapeuticproteinsinasequentialmannerfromplasma.

CollaborationrelyingonProMetic's MimeticLigandstechnologiesandAmericanRedCross'suniquecompetenciesinplasmaandbloodproducts,processandanalyticaldevelopment.

Resultedinthedevelopmentofaprocess(PPPS)capableofextractingsomeofthemostvaluableproteinsfromplasmaatmuchhigheryieldsthanotherprocesses.

PlasmaProteins

75%ofrevenuesaregeneratedwith4proteins:Albumin,IgG,FactorVIIIandAAT

74%ofrevenuesareusedby16%ofpopulation(NA,EU)

What is PPPSTM? Multiproductsequentialpurificationprocessoriginallydevelopedwith ARC. Proprietary platformderivedfromtheuseofPBLaffinitytechnology. DevelopedandcommercializedbyProMetics USbasedsubsidiary,PBT Using powerful affinity separation materials to extract and purify commerciallyUsingpowerfulaffinityseparationmaterialstoextractandpurifycommercially

valuableplasmaproteinsinhighyield.

Highlyefficientinextractingandpurifyingtherapeuticproteinsfromhumanplasma to develop best in class biotherapeutic productsplasmatodevelopbestinclassbio therapeuticproducts.

PPPSTM: The BenefitsPPPS :TheBenefits

Improvedeconomicsoverindustryaverages,through: improvedrecoveryyield, smallerfootprintforsamemanufacturingoutput, more product from less plasmamoreproductfromlessplasma

Improvedpurity

Improvedsafety pathogenremovalandviralinactivation

Recoveryofvaluableproteinstargetingrarediseases,potentiallyresultinginproductswithOrphanDrugDesignation

PPPSTM: The ProcessPPPS :TheProcess

TurnKeyProcess

PPPSTM:TheProducts&MarketOpportunitiesOpportunities

25

Orphan Drug DesignationOrphan DrugDesignation

Noveldrugsorbiologicsg g Treatmentofararediseaseorcondition Affectingfewerthan200,000patientsintheUS.g p SevenyearperiodofU.S.marketingexclusivityuponmarketingapproval

Taxcreditsforclinicalresearchcosts Abilitytoapplyforannualgrantfunding

l l h l d Clinicalresearchtrialdesignassistance Waiverofprescriptiondruguserfees.

TYPE1Plasminogen Deficiency Plasminogen: Plasminogen is a naturally occurring protein synthesized by Plasminogen: Plasminogen is a naturally occurring protein synthesized by

the liver and circulates in the blood. Plasmin is involved in wound healing,cell migration, tissue remodeling, angiogenesis and embryogenesis.

Type 1 Plasminogen Deficiency: One of the most welldefined conditionsassociated with plasminogen deficiency is ligneous conjunctivitis, which ischaracterized by thick, woody (ligneous) growths on the conjunctiva of the

d if l ft t t d l d t bli d M t ff t deye, and if left untreated, can lead to blindness. Most affected cases areinfants and children

Hypoplasminogenemia: multisystem disease that can also affect the earsHypoplasminogenemia: multisystem disease that can also affect the ears,sinuses, tracheobronchial tree, genitourinary tract, and gingiva.

OrphanDrugDiseasesTakingFrontStage

TheNationalInstitutesofHealthestimatesthatthereareapproximately7,0008,000rarediseasesaffecting25millionAmericans.Ararediseaseisdefinedasaconditionaffectingfewerthan200,000peopleintheUnitedStatesStates.

TheOrphanDrugAct(ODA)enactedin1983hasincreasedfrom10drugsin1983to382 in2011

UndertheODA,>2,500medicineshavebeendesignatedorphandrugsandareinallstagesofdevelopment

Orphandrugscurrentlymakeup22% oftotaldrugsales

Inthelast3years,35% ofFDAapproveddrugswereforOrphandiseases

In2011,35newmedicineswereapprovedbytheFDA:24NCEs,6

therapeuticbiologics,andfiveotherbiologics.11 ofthenewmedicinesh dareorphandrugs.

WeBelieve:InbuildingShareholderValue

Sales of Biopharmaceuticals

Sales of Bulk Active Ingredients

Royalties on Licencees' sales of Biopharmaceuticals

Sales of Affinity Resins to Licensees

0 10 20 30 40 50 60 70 80 90 100

29

Q12013FinancialResultsQ

ComparisonofKeyFinancials:P&LQ12013

Q12013CAD 000s

Q12012CAD 000sCAD000s CAD000s

Revenues 4,445 1,059

CostofGoods 1,347 916

Total Research & Development Costs 3 098 2 535TotalResearch&DevelopmentCosts 3,098 2,535

Administration&Marketing 1,519 1,397

FinanceCosts 354 352

NetLoss (2,093) (4,571)

NetLosspershare(basicanddiluted) (0.00) (0.01)

EBITDA* (1,321) (3,581)

*EBITDA is a nonGAAP measure, employed by the corporation to monitor its performance. Therefore it is unlikely to becomparable to similar measures presented by other companies. The corporation calculates its EBITDA by subtracting fromR it C t f G d S ld it R h d D l t E R h bl d N R h bl ll itRevenues, its Cost of Goods Sold, its Research and Development Expenses Rechargeable and NonRechargeable as well as itsAdministration and Marketing Expenses and excluding amortization of capital assets and licenses and patents.

31

ComparisonofKeyFinancials:B l Sh tBalanceSheet

Mar312013CAD000s

Dec312012CAD000s

Cash 7,549 1,205

Accounts Receivable 3,695 4,750AccountsReceivable 3,695 4,750

ShareSubscriptionReceivable 9,822

Inventories 2,498 1,238

BankandOtherLoans 700 1,636

Trade&OtherPayables 5,041 5,094

DeferredRevenues 1,212 2,355

LongtermDebtProvidedbyShareholders 3,135 4,017

AdvanceonRevenuesfromaSupplyAgreement 2,919 3,030

NetEquity 6,258 5,819

32

Estimated 2013 Revenue vs. 2012

30

Estimated2013Revenuevs.2012

n

20

25

$

M

i

l

l

i

o

n

15

20

2012

E. 2013

5

10

E.2013

0

5

H1 H2 YEARH1 H2 YEAR

E.2013aheadof2012by~$3,3MinQ1

PotentialRevenueMix

120

l

l

i

o

n

80

100

$

M

i

40

60

0

20

2013 2014 2015 2016 2017

Salesofaffinity filters /bioseparation products

Productdevelopment servicerevenues

Plasmaderived proteins /biopharmaceuticals

$250M

$200M

$150M

ProMetics totalrevenuesfromtheProteinTechnologiessegmentwillbeinfluencedbytheexactmixof:

$100MProductsmanufacturedforlicenseesandMarketedbylicenseesRoyaltiesfromlicenseesProducts manufactured and marketed by $50MProductsmanufacturedandmarketedbyProMetic &marketingpartners

200820092010201120122013201420152016 201720182019

Key2013Objectives

Plasmaderived Therapeutics: Plasmaderived Therapeutics: OperationallaunchofProMeticBioProductionInc. Secureorphan drug designations

SmallMolecule Therapeutics:Ad l d d t li i l t i l t Advanceleadcompoundtoclinicaltrialstage

Developandenterintonewprograms/strategicalliances

QUESTIONANDQANSWERPERIOD